Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$469.57
-8.1%
$597.54
$387.12
$672.19
$146.52B1.332.33 million shs8.10 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$737.56
-6.5%
$848.36
$711.40
$972.53
$699.95B0.513.33 million shs5.29 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$62.58
-6.7%
$80.85
$62.37
$148.15
$280.84B0.615.64 million shs10.85 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$22.62
-6.6%
$29.32
$21.53
$81.86
$2.54B0.843.93 million shs6.56 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%-13.53%-17.13%-19.06%+13.42%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-10.09%-19.19%-5.68%-4.99%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%-9.77%-28.85%-28.60%-50.72%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%-11.81%-21.13%-47.26%-71.16%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.9978 of 5 stars
4.25.04.23.02.43.33.8
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8969 of 5 stars
3.45.03.34.03.32.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8086 of 5 stars
4.45.02.50.02.80.04.4
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.365 of 5 stars
4.51.00.04.73.43.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.42
Hold$589.1925.47% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7236.90% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25132.10% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$95.18320.79% Upside

Current Analyst Ratings Breakdown

Latest VKTX, NVO, LLY, and GS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$560.00
4/3/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$625.00 ➝ $614.00
4/1/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$660.00 ➝ $594.00
3/28/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$720.00 ➝ $680.00
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/25/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$605.00 ➝ $625.00
3/24/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$585.00 ➝ $550.00
3/19/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/13/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$782.00 ➝ $659.00
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/11/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$53.51B2.74$29.99 per share15.66$324.13 per share1.45
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.53$12.02 per share61.34$15.05 per share49.01
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B0.97$2.90 per share21.57$4.64 per share13.49
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.28B$40.5511.589.020.8911.32%13.30%0.84%4/14/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7162.9923.701.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2919.0213.430.9034.81%84.68%26.29%5/7/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.00N/AN/AN/AN/A-11.93%-11.57%4/23/2025 (Estimated)

Latest VKTX, NVO, LLY, and GS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
5/1/2025N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92N/AN/AN/AN/AN/A
4/23/2025N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.34N/AN/AN/AN/AN/A
4/14/2025N/A
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.57N/AN/AN/A$14.99 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
2/5/2025Q4 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.32-$0.05-$0.32N/AN/A
1/15/2025Q4 2024
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$8.21$11.95+$3.74$11.95$12.36 billion$13.87 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.002.56%+20.95%29.59%13 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.81%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.51%+25.26%47.72%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, NVO, LLY, and GS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
1/15/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$3.002%2/28/20252/28/20253/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.32
0.67
0.67
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
48,500312.04 million310.35 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.25 million106.20 millionOptionable

Recent News About These Companies

The Smartest Biotech Stocks to Buy With $50

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$469.57 -41.66 (-8.15%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$468.88 -0.69 (-0.15%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$737.56 -51.53 (-6.53%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$717.25 -20.31 (-2.75%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$62.58 -4.52 (-6.73%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$61.58 -1.01 (-1.61%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$22.62 -1.60 (-6.61%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$22.02 -0.60 (-2.63%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.